Tempus AI’s COO Ryan Fukushima sells shares value $140,805

Ryan Fukushima, Chief Working Officer of Tempus AI, Inc. (NASDAQ:TEM), has reported the sale of three,500 shares of Class A Frequent Inventory. The shares had been bought at a median worth of $40.23 per share, amounting to a complete transaction worth of roughly $140,805. The inventory has since declined to $34.30, a part of a broader 7.24% decline over the previous week, in response to InvestingPro knowledge.

This sale was carried out to cowl statutory tax withholding obligations associated to the vesting of restricted inventory items, as mandated by Tempus AI’s fairness incentive plans. Following the transaction, Fukushima holds 1,003,707 shares instantly. Moreover, there are 131,893 shares held not directly by the Ryan Fukushima Irrevocable Household Belief and 150,000 shares held by his partner. The corporate, at the moment valued at $6.13 billion, has proven robust income progress of 32.13% and maintains wholesome liquidity with a present ratio of two.69.

Buyers will be aware that the sale was a non-discretionary motion required by firm coverage slightly than a voluntary resolution by Fukushima. InvestingPro subscribers can entry further insights, together with a number of analyst revisions and detailed monetary well being metrics, to higher perceive TEM’s present market place.

In different latest information, Tempus AI has been the topic of a number of analyst changes following its latest earnings report. Piper Sandler notably elevated its worth goal from $40 to $70, whereas sustaining a Impartial ranking on the shares. The acquisition of genetics agency Ambry, nonetheless, was not factored into these estimates. Stifel additionally adjusted its stance on Tempus AI, downgrading the inventory from Purchase to Maintain, however concurrently elevating its worth goal to $65. Needham, however, elevated its inventory worth goal to $56 and maintained a Purchase ranking.

Tempus AI’s acquisition of Ambry Genetics is seen as a strategic transfer, introducing rapid genomics capabilities and offering alternatives in knowledge and purposes over time. The corporate has additionally partnered with Avacta Therapeutics to make the most of AI in advancing oncology drug growth. This collaboration will present Avacta entry to Tempus’s complete multimodal datasets.

As well as, Tempus AI’s CEO, Eric Lefkofsky, has deferred the settlement of roughly 4.47 million restricted inventory items to a interval between January 15, 2025, and March 15, 2025. The corporate has additionally invested $36 million in Personalis (NASDAQ:PSNL), Inc., buying shares and exercising warrants for added inventory. Lastly, Tempus AI’s Tempus ECG-AF machine, which makes use of synthetic intelligence to establish sufferers at larger threat of atrial fibrillation/flutter, just lately obtained FDA clearance. These are the latest developments surrounding Tempus AI.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.